Document:

Agreement

 Exhibit 4.19 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED. 
 AGREEMENT 

FOR THE PROVISION OF THERAPEUTIC APHERESIS AND CVACTM 
 IN DUBAI HEALTHCARE CITY 
 AUGUST 1, 2011 

PRIMA BIOMED MIDDLE EAST FZ LLC 
 AND 
 THE CITY HOSPITAL FZ LLC 

 This Agreement for the Provision of Therapeutic Apheresis and CVac in Dubai Healthcare
City (the “Agreement”), effective as of August 1, 2011, is entered into by and between: 
  

			
	(1)	  	 Prima BioMed Middle East FZ LLC, a free zone limited liability company formed under the laws of Dubai Healthcare City (“DHCC”) in the United
Arab Emirates (“UAE”) and whose principal address is Unit 2009 Building 64 Dubai Healthcare City, Dubai, UAE (“Prima”); and

		
	(2)	  	 The City Hospital FZ LLC, a free zone limited liability company to operate a hospital formed under the laws of DHCC in the UAE and whose principal
address is P.O.Box 505004, Dubai Healthcare City, Dubai, UAE (“The City Hospital”);

	
	 Prima and The City Hospital shall be referred to as the “Parties” or, individually, a
“Party”.

 BACKGROUND 
 Whereas, 
  

					
		  	 (a)
	  	 Prima maintains resources, staffing, and equipment to support the provision of apheresis; and

			
		  	 (b)
	  	 Prima, as a wholly-owned subsidiary of Prima BioMed Ltd. (Australia), has the rights to CVac, an autologous immunotherapeutic, intended for treatment of
certain cancers (CVac Program is defined in Schedule B in more detail); and

			
		  	 (c)
	  	 The City Hospital is a full service hospital in DHCC and has the clinical resources, staffing, and facilities to provide therapeutic apheresis services and to
administer CVac in its facilities;

 Now, therefore, Prima and The City Hospital agree to provide their mutual Services in support of the
Therapeutic Apheresis Program and the CVac Program in DHCC under the terms and conditions set out in this Agreement. 
 INTERPRETATION

  

			
	  1.2	  	 In this Agreement:

		
		  	 Affiliate means in relation to any Party, any other entity which directly or indirectly Controls, is Controlled by or is under direct or indirect
common Control with, that Party from time to time;

		
		  	 Agreed Form means in relation to any document, the form of that document which has been agreed to by Prima and City Hospital;

		
		  	 Agreement means this agreement, including its Schedules, Appendices and Annexes, and future, duly executed amendments and addenda;

  
 [ * ] =
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 
  
  

 

			
	The City Hospital – Prima Apheresis and CVacTM Agreement	  	Page 1

			
		  	 Business Day means a day (other than a Friday or Saturday) on which banks are generally open for normal business in the UAE;

		
		  	 The City Hospital Services means the service or services that are the responsibility of City Hospital under this Agreement to support the Therapeutic
Apheresis Program and CVac Program, defined in further detail in Schedule C;

		
		  	 The City Hospital Personnel means all employees, agents and consultants of The City Hospital engaged in the provision of The City Hospital Services,
including any physician that would be allowed to prescribe CVac;

		
		  	 Control means in relation to an entity or a person, the indirect or direct ownership of more than 50% of the voting capital or similar right of
ownership of that entity or person or the legal power to direct or cause the direction of the general management and policies of that entity or person, whether through the ownership of voting capital, by contract or otherwise, and Controls
and Controlled shall be interpreted accordingly;

		
		  	 CVac means autologous dendritic cells pulsed with the recombinant human fusion protein Mucin1-Glutathione S Transferase which is coupled to oxidized
polymannose

		
		  	 CVac Process means the provision of all necessary steps to obtain enough CVac for one patient to receive [ * ] of CVac

		
		  	 CVac Program means all activities related to the preparation and administration of CVac, including but not limited to [ * ], as detailed in Schedule
B;

		
		  	 Good Manufacturing Practice and GMP means the manufacturing practices and principles promulgated by the International Conference on Harmonization, as
revised from time to time, related to the production of medicinal products such as CVac;

		
		  	 Group means, in relation to a company, that company and its Affiliates;

		
		  	 Intellectual Property Rights means all intellectual property rights worldwide arising under statutory or common law or by contract and whether or not
perfected, now existing or hereafter filed, issued, or acquired including all (a) patent applications containing one or more claims, (b) provisional applications, (c) non-provisional, continuation, continuation-in-part, and divisional
applications that claim the priority of any patent rights described in (a) or (b) above, and (d) patents issuing on patent rights described in (a) and (c) above and reissues, reexaminations, and extensions thereof; rights
relating to the protection of trade secrets and Proprietary Information; and any right analogous to those set forth herein and any other proprietary rights relating to intangible property, other than trademarks and service
marks.

		
		  	 Invention means any and all ideas, concepts, inventions, discoveries, techniques, processes, machines, manufactures, reports, writings, methods,
developments, improvements, designs, systems, specifications, schematics, drawings, information, protocols, devices (including, without limitation, prototypes), works of authorship, formulae, algorithms, computer programs, trade secrets, technology,
know-how, evaluations, studies, analytical results, assays, data, specifications, technical information, and samples, whether or not patentable.

  
 [ * ] =
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 
  
  

 

			
	 The City Hospital – Prima Apheresis and CVacTM Agreement
	  	Page 2

			
		  	 Laws means all applicable laws, enactments, regulations, regulatory policies, guidelines, industry codes, regulatory permits and licenses which are in
force from time to time during the Term and are applicable to the Programs or Services subject to this Agreement;

		
		  	 Loss means any loss, damage, fine, penalty, cost, expense or other liability (including legal and other professional fees) and Losses shall be
interpreted accordingly;

		
		  	 Net Fees means the net of the gross procedure tariff less of any discounts agreed by third party payer or self paying patient.

		
		  	 Prima Services means the service or services that are the responsibility of Prima under this Agreement to support the Therapeutic Apheresis Program and
CVac Program, defined in further detail in Schedule D;

		
		  	 Prima Personnel means all employees, agents and consultants of Prima engaged in the provision of the Prima Services;

		
		  	 Programs means both Therapeutic Apheresis Program and CVac Program

		
		  	 Proprietary Information means any scientific, technical, trade or business information possessed or obtained by, developed for or given to Prima which
is treated by Prima as confidential or proprietary, whether or not labeled as confidential and/or proprietary. Proprietary Information may include information that is confidential and proprietary to one or more third parties that has been provided
to Prima for use in conjunction with the Programs. Proprietary Information will include, without limitation, data and procedures related to Therapeutic Apheresis and CVac and correspondence between the Parties. Proprietary Information does not
include information which (a) was already known to The City Hospital prior to the time it was disclosed, other than by previous disclosure by Prima, as evidenced by The City Hospital’s written records at the time of disclosure, (b) is
at the time of disclosure or later becomes publicly known under circumstances involving no breach of this Agreement, (c) is lawfully and in good faith made available to The City Hospital without obligations of confidentiality by a third party
who did not, to The City Hospital’s knowledge, derive it, directly or indirectly, from Prima, or (d) was independently developed by The City Hospital, as evidenced by credible written records, without use of Proprietary
Information.

		
		  	 Regulator means any entity or person having regulatory or supervisory authority over all or any part of (a) Laws, (b) The City Hospital or
Prima Services, or (c) the business of Prima or The City Hospital or any of their Affiliates;

		
		  	 Services means both The City Hospital Services and Prima Services

  
 [ * ] =
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 
  
  

 

			
	The City Hospital – Prima Apheresis and CVacTM Agreement	  	Page 3

					
		  	 Tax means any sales, purchase or turnover tax as maybe applicable in any relevant jurisdiction;

		
		  	 Term means the period from the date first written above until the date on which this Agreement is terminated in accordance with Clause 14 or
by Law;

		
		  	 Therapeutic Apheresis means a medical technology in which the blood of a patient or donor is passed through an apheresis machine that
separates out a particular component (or particular components) of the blood and returns the rest of the blood to the patient or donor;

		  	 Therapeutic Apheresis Process means the provision of one apheresis procedure, and related activities, for a single patient or
donor;

		
		  	 Therapeutic Apheresis Program means all activities related to the provision of apheresis in The City Hospital including, but not limited to, [
* ], as detailed in Schedule A;

		
		  	 Third-Party means any person or entity which is not a Party to this Agreement; and

		
	 1.1
	  	 In this Agreement any reference, express or implied, to an enactment (which includes any legislation in any jurisdiction)
includes:

			
		  	 (a)
	  	 that enactment as amended, extended or applied by or under any other enactment before, on or after the date of this Agreement;

			
		  	 (b)
	  	 any enactment which that enactment re-enacts (with or without modification); and

			
		  	 (c)
	  	 any subordinate legislation made (before, on or after the date of this Agreement) under that enactment, including (where applicable) as amended, extended, or
applied as described in paragraph (a) above, or under any enactment which it re-enacts referred to in paragraph (b) above.

		
	 1.2
	  	 In this Agreement:

			
		  	 (a)
	  	 any reference to a person includes a body corporate, unincorporated, association of persons (including a partnership), government, state, agency,
organisation, and any other entity whether or not having a separate legal personality and an individual, his estate and personal representatives;

			
		  	 (b)
	  	 subject to Clause 15, any reference to a Party includes the successors or assigns (immediate or otherwise) of that Party;

			
		  	 (c)
	  	 the words including and include shall mean including without limitation and include without limitation, respectively;

			
		  	 (d)
	  	 any reference importing a gender includes the other genders;

			
		  	 (e)
	  	 any reference to a time of day is to Dubai time;

  
 [ * ] =
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 
  
  

 

			
	The City Hospital – Prima Apheresis and CVacTM Agreement	  	Page 4

					
		  	 (f)
	  	 any reference to a document is to that document as amended, varied or novated from time to time otherwise than in breach of this Agreement or that
document;

			
		  	 (g)
	  	 any reference to a Section, Clause, Subclause, Schedule or Appendix is to a Section, Clause, Subclause, Schedule or Appendix to this
Agreement;

			
		  	 (h)
	  	 the schedules and appendices form part of this Agreement; and

			
		  	 (i)
	  	 the headings do not affect the interpretation of this Agreement.

		
	 1.3
	  	 If there is any conflict or inconsistency between any of:

			
		  	 (a)
	  	 a term in the main part of this Agreement;

			
		  	 (b)
	  	 a term in any of the schedules, including the appendices to the schedules; and

			
		  	 (c)
	  	 any term included in any other document incorporated by reference into this Agreement,

		
		  	 the term falling into the category first appearing in the list above shall, unless expressly stated otherwise, take precedence.

		
	 1.4
	  	 The ejusdem generis rule does not apply to this Agreement. Accordingly, specific words indicating a type, class or category of thing do not
restrict the meaning of general words following specific words, such as general words introduced by the word other or a similar expression. Similarly, general words followed by specific words shall not be restricted in meaning to the type, class or
category of thing indicated by the specific words.

		
	 2.
	  	 PROVISION OF SERVICES

		
	 2.1
	  	 Prima and The City Hospital agree to provide for the mutual Services of each Party, as detailed in Schedules C and D, to support the Therapeutic
Apheresis Program and the CVac Program, as detailed in Schedules A and B, in accordance with the terms of this Agreement, GMP, and all relevant Laws.

		
	 2.2
	  	 Part or all of Prima’s Services may be provided by one or more of Prima’s Affiliates.

		
	 2.3
	  	 The Parties shall ensure that each of their obligations under this Agreement are performed by appropriately experienced, qualified, competent,
trained and efficient personnel.

		
	 2.4
	  	 Each Party shall obtain and maintain throughout the Term, at its own cost, all those consents, licenses and authorisations as are necessary to
properly perform its mutual services and obligations under this Agreement.

  
 [ * ] =
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 
  
  

 

			
	The City Hospital – Prima Apheresis and CVacTM Agreement	  	Page 5

									
	 3.
	  	 COMPENSATION

		
	 3.1
	  	 The City Hospital is responsible for billing patients, or Third-Party payors, and collection of fees related to both Programs according to City
Hospital’s standard tariff and processes for billing and collections.

		
	 3.2
	  	 The City Hospital is then responsible for compensating Prima as follows:

			
		  	 (a)
	  	 For the Therapeutic Apheresis Program, The City Hospital shall pay Prima [ * ] of the Net Fees received by The City Hospital for each
Therapeutic Apheresis Process. Net Fees, for the purpose of this section 3.2(a), shall mean the fees actually received by The City Hospital from patients, or Third-Party payors on behalf of patients, less out-of-pocket, unreimbursed costs incurred
by The City Hospital for consumables and concomitant medications directly related to provision of Therapeutic Apheresis Processes.

			
		  	 (b)
	  	 For CVac Program, The City Hospital shall pay Prima as follows:

				
		  		  	 (i)
	  	 For each CVac Process that yields [ * ] of CVac which are safely delivered (subject to confirmation from The City Hospital or Associate treating
Oncologist) to City Hospital, regardless of the number of doses actually administered to a patient, The City Hospital shall pay Prima [ * ] United States Dollars (USD [ * ]).

				
		  		  	 (ii)
	  	 For a CVac Process that yields less than [ * ] of CVac, The City Hospital may, at its discretion, either:

					
		  		  		  	 (A)
	  	 Accept delivery of the actual number of CVac doses yielded at a prorated cost of [ * ] United States Dollars (USD [ * ]) per vial; or

					
		  		  		  	 (B)
	  	 Request a repeat of the CVac Process with agreement from the patient, at Prima’s expense. In such case, Prima will deliver and The City Hospital will
accept delivery of the actual number of vials produced during the two CVac Processes at a prorated cost of [ * ] United States Dollars (USD [ * ]) per vial; however,

					
		  		  		  	 (C)
	  	 In any case, The City Hospital has the right to reject delivery of and not pay for a CVac Process (or CVac Processes) that yield [ * ] of CVac for a
patient.

				
		  		  	 (iii)
	  	 If a CVac Process yields more than [ * ] of CVac, Prima will inform The City Hospital. Prima will maintain and store the extra vials until
the expiration date for CVac (currently estimated as [ * ] from the manufacturing date, but subject to change). In the event that the prescribing physician requests the extra doses for administration prior to the expiration date, Prima will deliver
the requested number and The City Hospital shall pay [ * ] United States Dollars (USD [ * ]) for each additional dose.

  
 [ * ] =
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 
  
  

 

			
	The City Hospital – Prima Apheresis and CVacTM Agreement	  	Page 6

					
	 3.3
	  	 The City Hospital shall maintain bookkeeping and accounting records sufficient to demonstrate its compliance with its compensation obligations and
such records shall be available for review by Prima with reasonable advance notice.

		
	 4.
	  	 INVOICING AND PAYMENT

		
	 4.1
	  	 For the Therapeutic Apheresis Program:

			
		  	 (a)
	 	 The City Hospital shall provide Prima a statement, no less than on a [ * ] basis, of all Therapeutic Apheresis Processes completed in the period, as well as
an accounting of fees billed and received for those Therapeutic Apheresis Processes.

			
		  	 (b)
	 	 Prima will verify the accuracy of each such statement and then present an invoice to The City Hospital for [ * ] of the Net Fees, as defined in section
3.2(a), actually received by The City Hospital in that period.

		
	 4.2
	  	 For the CVac Program, Prima will invoice The City Hospital at the time of shipment of CVac doses to The City Hospital.

		
	 4.3
	  	 In the event that The City Hospital incurs expenses that are related to Prima Services as defined in Schedule D, The City Hospital shall
provide Prima a statement of all such expenses and Prima shall issue a credit memo to The City Hospital for such expenses. The City Hospital shall apply such credits to Prima invoices as The City Hospital chooses. Consumable supplies for either
the Apheresis Program for CVac Program such as [ * ], will be procured and charged by The City Hospital

		
	 4.4
	  	 The fees agreed to herein are exclusive of any Tax.

		
	 4.5
	  	 All Prima invoices are payable within [ * ] of receipt of the relevant invoice.

		
	 4.6
	  	 All invoices shall be in UAE Dirhams.

		
	 5.
	  	 EXCLUSIVITY AND NON-COMPETITION

		
	 5.1
	  	 The City Hospital and Prima agree that all exclusivity and non-competition provisions in this Agreement are reasonable and necessary to protect
the mutual interests of the Parties and that neither Party would have entered into this Agreement without these exclusivity and non-competition provisions.

		
	 5.2
	  	 The City Hospital agrees that all property provided by Prima to The City Hospital (including but not limited to [ * ]) is for the sole use of the
Apheresis and CVac Programs and shall not be utilized for any other purpose.

  
 [ * ] =
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 
  
  

 

			
	The City Hospital – Prima Apheresis and CVacTM Agreement	  	Page 7

			
	 5.3
	 	 The City Hospital agrees that apheresis technician(s) that are paid for by Prima shall be dedicated exclusively to the Apheresis and CVac
Programs.

		
	 5.4
	 	 The City Hospital agrees, for the term of this Agreement not to directly or indirectly [ * ], without the prior written consent of Prima. If another
company approaches The City Hospital offering services that Prima cannot provide [ * ] The City Hospital can enter into an agreement without consent or approval of Prima.

		
	 5.5
	 	 Prima agrees, for the term of this Agreement, not to directly or indirectly [ * ], without the prior written consent of The City
Hospital.

		
	 6.
	 	 REGULATORY COMPLIANCE

		
	 6.1
	 	 Each Party shall comply with all Applicable Laws and Regulations in performing its obligations under this Agreement.

		
	 6.2
	 	 Each Party shall continue to hold all regulatory approvals from Regulators which are necessary in order for it to perform its obligations under this
Agreement.

		
	 7.
	 	 OWNERSHIP

		
	 7.1
	 	 It is expressly agreed to and acknowledged by the Parties that Prima, at all times, shall retain ownership of, and title in, any capital equipment delivered
to The City Hospital in relation to this Agreement, such as an apheresis machine or any other similar equipment.

		
	 7.2
	 	 With regards to the CVac Program, Prima shall take ownership of a patient’s cells from the time CVac-specific apheresis is started. The City Hospital
shall ensure that all patients are informed of this provision and that it is expressly agreed to by each patient in writing prior to commencement of a CVac Process. Prima warrants that it will not use a patient’s cells for any purpose other
than to attempt the production of CVac. Any unused cells or any unused CVac will be destroyed by Prima.

		
	 8.
	 	 INTELLECTUAL PROPERTY RIGHTS AND PROPRIETARY INFORMATION

		
	 8.1
	 	 Any inventions, methods, developments, and discoveries whether patentable or not, relating to or arising from the Therapeutic Apheresis Program or CVac
Program, or made in the performance of work under this Agreement shall be governed by UAE patent law.

		
	 8.2
	 	 The City Hospital hereby acknowledges and agrees that it shall not acquire any rights in the Inventions or Proprietary Information of Prima, and that Prima
retains all rights, including Intellectual Property Rights, in and to its Inventions and Proprietary Information.

		
	 8.3
	 	 The parties hereto acknowledge and agree that Prima shall be the sole and exclusive owner of all right, title and interest in and to any improvements or
Inventions conceived, created, developed or reduced to practice as a result of the conduct of the

  
 [ * ] =
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 
  
  

 

			
	The City Hospital – Prima Apheresis and CVacTM Agreement	  	Page 8

			
		  	 Programs, whether by Prima Personnel or The City Hospital Personnel, or jointly by both Prima Personnel and The City Hospital Personnel. The City Hospital agrees
that all Inventions that are copyrightable subject matter shall be considered “work made for hire” within the meaning of the copyright laws of the United States and that Prima shall be the sole author of such Inventions and the sole owner
of all rights therein.

		
	 8.4
	  	 In furtherance of the foregoing, and to the extent permitted by law, The City Hospital hereby irrevocably and unconditionally transfers and assigns to Prima, its
successors, and assigns, all right, title and interest that it may have or acquire in or to any such Prima Inventions, including all Intellectual Property Rights therein. The City Hospital agrees that it shall notify Prima, promptly upon their
discovery of an Invention and in any event upon the request of Prima, of any Prima Inventions made or developed by City Hospital or any of The City Hospital Personnel. Upon request by Prima, The City Hospital agrees that it shall execute and deliver
or cause the execution and delivery of all such documents, certificates, assignments and other writings, and take such other actions as may be necessary or desirable to vest in Prima the ownership rights granted to Prima hereunder, including without
limitation the execution and delivery of all appropriate applications for securing all patents, copyrights and other Intellectual Property Rights relating to the Prima Inventions. Prima shall reimburse The City Hospital for any reasonable expenses
incurred at Prima’s request to secure title or legal protection on Prima’s behalf for any such Prima Inventions.

		
	 8.5
	  	 The City Hospital shall own all right, title and interest in and to any and all Inventions which are conceived, made or reduced to practice solely by The City
Hospital Personnel, independently from and without assistance from Prima Personnel, Prima Inventions, or Prima’s Proprietary Information.

		
	 8.6
	  	 All technology and Intellectual Property Rights owned by a Party as of the date of this Agreement shall remain the property of such Party and no licenses or
other rights with respect to such technology or Intellectual Property Rights are granted to any other party except as expressly set forth in this Agreement. Nothing in this Agreement shall be construed as granting any party any right or license
under any Intellectual Property Rights, trademarks, or service marks of any other party by implication, estoppel or otherwise, except as expressly set forth in this Agreement.

		
	 8.7
	  	 To the extent that Prima discloses to The City Hospital (or has disclosed to The City Hospital) Proprietary Information to assist The City Hospital in conducting
the Programs, Prima hereby grants to The City Hospital, subject to the terms and conditions of this Agreement, a [ * ] license to use such Proprietary Information solely in connection with The City Hospital’s Services. The City Hospital will
use Proprietary Information solely for the purpose of furthering the goals of the Programs under this Agreement and for no other purpose.

		
	 8.8
	  	 Starting on the effective date of this Agreement and for a period of [ * ] after termination of this Agreement The City Hospital will not publish,
disseminate or otherwise disclose, deliver or make available to any third party other than Prima Personnel, any Proprietary Information excluding patient medical records, other than

  
 [ * ] =
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 
  
  

 

			
	 The City Hospital – Prima Apheresis and CVacTM Agreement
	  	Page 9

			
		  	 in furtherance of the purposes of this Agreement, and only then with the prior written consent of Prima. The City Hospital may disclose Proprietary Information
to a Regulator or by order of a court of competent jurisdiction, provided that such disclosure is subject to all applicable governmental or judicial protection available for like material and reasonable advance notice is given to Prima, where
feasible.

		
	 8.9
	  	 The City Hospital will immediately notify Prima in the event of any loss or unauthorized disclosure of any Proprietary Information.

		
	 8.10
	  	 The City Hospital acknowledges and agrees that damages may not be an adequate remedy in the event of a breach of any of their obligations under this section. The
City Hospital therefore agrees that Prima shall be entitled (without limitation of any other rights or remedies otherwise available to Prima) to obtain, without posting bond, specific performance and preliminary and permanent injunction from any
court of competent jurisdiction prohibiting the continuance or recurrence of any breach of this section.

		
	 8.11
	  	 The City Hospital agrees that, except as expressly permitted under this section, The City Hospital Personnel shall not discuss Proprietary Information regarding
the Study or CVac with any person for any reason and shall not express any opinion that is informed, in whole or in part, whether directly or indirectly, by access to the Proprietary Information. For the avoidance of doubt, The City Hospital
personnel performing Study activities shall not discuss Proprietary Information regarding CVac of the Programs with any financial, securities, industry analyst, or with the media.

		
	 9.
	  	 INDEMNIFICATION AND INSURANCE

		
	 9.1
	  	 Prima agrees to defend, indemnify and hold harmless The City Hospital and The City Hospital’s officers, directors, employees, affiliated doctors and agents
against any independent third party claims (“Claims”) arising out of any breach of this Agreement by Prima, except to the extent a Claim arises out of (a) the negligence, willful misconduct or wrongful acts or omissions of The City
Hospital or any of The City Hospital’s officers, directors, employees, affiliated doctors and agents, or, (b) the failure of The City Hospital to adhere to the terms of this Agreement (including the Schedules) or other written instructions from
Prima or its designees or to comply with any applicable laws, governmental requirements or Good Clinical Practices. This indemnification is contingent on The City Hospital providing Prima with prompt written notice of a Claim (provided, however,
that a delay in notification shall not relieve Prima of its indemnification obligations hereunder, unless such delay adversely effects Prima’s rights hereunder) and full authority to defend against, and/or settle the Claim. In addition, The
City Hospital shall cooperate fully with Prima and its legal counsel in the investigation and/or defense of any Claims at Prima’s expense. Prima shall not settle any Claim that involves an admission of liability or wrongdoing by, or imposes any
obligations on, The City Hospital without The City Hospital’s prior written consent, which consent shall not be unreasonably withheld.

		
	 9.2
	  	 The City Hospital agrees to defend, indemnify and hold harmless Prima, its directors, officers, staff, employees and agents against any Claims arising out the
negligence,

  
 [ * ] =
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 
  
  

 

			
	 The City Hospital – Prima Apheresis and CVacTM Agreement
	  	Page 10

					
		  	 willful misconduct, wrongful acts or omissions of The City Hospital or any of The City Hospital’s officers, directors, employees, affiliated
doctors and agents, or the failure of The City Hospital to adhere to the terms of this Agreement (including the Schedules) or other written instructions from Prima or its designees or to comply with any applicable laws or governmental requirements.
This indemnification is contingent on Prima providing The City Hospital with prompt written notice of a Claim and full authority to defend against, and/or settle the Claim. In addition, Prima shall cooperate fully with The City Hospital and its
legal counsel in the investigation and/or defense of any Claims at The City Hospital’s expense. The City Hospital shall not settle any Claim that involves an admission of liability or wrongdoing by, or imposes any obligations on, Prima without
Prima’s prior written consent, which consent shall not be unreasonably withheld.

		
	 9.3
	  	 The City Hospital represents that it has and will maintain, at its own cost, during the entire Term of this Agreement, professional liability and
comprehensive general liability insurance in amounts commercially reasonable to cover risks associated with City Hospital Services and City Hospital indemnification of Prima. City Hospital will provide written evidence of such insurance to Prima
upon request, and will provide written notice at least [ * ] prior to the cancellation, non-renewal or material change in such insurance.

		
	 9.4
	  	 Prima represents that it has and will maintain, at its own cost, during the entire Term of this Agreement, products liability and professional
liability insurance in amounts commercially reasonable to cover risks associated with Prima Services and Prima indemnification of City Hospital. Prima will provide written evidence of such insurance to City Hospital upon request, and will provide
written notice at least [ * ] prior to the cancellation, non-renewal or material change in such insurance.

		
	 10.
	  	 REPRESENTATIONS, WARRANTIES AND UNDERTAKINGS

		
	 10.1
	  	 Each Party represents and warrants to the other Party that:

			
		  	 (a)
	  	 it has the power to execute and deliver this Agreement and to perform its obligations under it and has taken all action necessary to authorise execution and
delivery and the performance of its obligations;

			
		  	 (b)
	  	 this Agreement constitutes legal, valid and binding obligations of that Party in accordance with its terms; and

			
		  	 (c)
	  	 authorisations, licences or consents from, and notices or filings with, any relevant Regulator or other governmental or other authority that are necessary to
enable it to execute, deliver and perform its obligations under this Agreement have been obtained or made (as the case may be) and are in full force and effect and all conditions of each authorisation, licence, consent, notice or filing have been
complied with.

		
	 10.2
	  	 TO THE EXTENT APPLICABLE, EXCEPT AS EXPRESSLY PROVIDED HEREIN, ALL DATA, PRODUCTS, AND INVENTIONS, IF ANY, PROVIDED, SUBMITTED OR GENERATED
HEREUNDER BY PRIMA OR PRIMA

  
 [ * ] =
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 
  
  

 

			
	 The City Hospital – Prima Apheresis and CVacTM Agreement
	  	Page 11

					
		  	 PERSONNEL, IS PROVIDED, SUBMITTED OR GENERATED, AS APPLICABLE, “AS-IS” WITH NO WARRANTY OF ANY KIND, AND ALL SUCH WARRANTIES THEREIN,
WHETHER STATUTORY, EXPRESS OR IMPLIED (AND INCLUDING WITHOUT LIMITATION WARRANTIES OF FITNESS FOR A PARTICULAR PURPOSE, MERCHANTABILITY, TITLE AND NON-INFRINGEMENT OF THIRD PARTY RIGHTS), ARE HEREBY DISCLAIMED TO THE MAXIMUM EXTENT PERMISSIBLE BY
LAW. Nothing in this section shall be deemed to reduce or affect in any way Prima’s indemnification obligations set forth in this Agreement. Except with respect to its indemnification obligations explicitly set forth herein, Prima shall have no
liability to The City Hospital or The City Hospital Personnel for any lost profits, lost opportunities, or consequential, special, incidental, indirect or punitive damages.

		
	11.	  	FORCE MAJEURE
		
	 11.1
	  	 Neither Party shall be liable to the other Party for any delay or non-performance of its obligations under this Agreement arising directly from any
of the following cause or causes beyond its reasonable control and unable reasonably to be planned for or avoided: act of God, governmental act, act of terrorism, war, earthquake, flood, embargo, riot, sabotage, strike (other than of its own
employees), failure of Third-Party telecommunications networks, failures of Third-Parties (other than Subcontractors), explosion or civil commotion (“Force Majeure Event”), provided that the affected Party:

			
		  	 (a)
	  	 promptly notifies the other Party in writing of the cause of the delay or non-performance and the likely duration of the delay or non-performance;
and

			
		  	 (b)
	  	 uses all reasonable endeavours to limit the effect of that delay or non-performance on the other Party.

		
	 11.2
	  	 In any such case, the performance of the affected Party’s obligations, to the extent affected by the cause, shall be suspended during the period
that the cause persists.

		
	12.	  	TERM AND TERMINATION
		
	 12.1
	  	 This Agreement shall commence on the Effective Date and shall continue in force for one (1) year (the “Term”) unless earlier
terminated or extended in writing.

		
	 12.2
	  	 Each Party shall have the right, without prejudice to its other rights or remedies, to terminate this Agreement by written notice to the other Party
if:

			
		  	 (a)
	  	 the other Party is unable to pay its debts or becomes insolvent, or an order or an application is made or a resolution passed for the administration, winding-up
or dissolution of the other Party (otherwise than for the purposes of a solvent amalgamation or reconstruction), or an administrative or other receiver, manager, liquidator, administrator, trustee or similar officer is appointed over all or any of
the assets of the other Party, or the other Party enters into or proposes any composition or arrangement with its creditors generally or a moratorium is declared in respect of its indebtedness or any other creditor action or anything analogous to
the foregoing occurs in any applicable jurisdiction;

  
 [ * ] =
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 
  
  

 

			
	 The City Hospital – Prima Apheresis and CVacTM Agreement
	  	Page 12

					
		 	 (b)
	  	 the other Party is in material breach of this Agreement (being a single event or a series of events which are together a material breach) and either that
breach is not capable of remedy or, if the breach is capable of remedy that other Party has failed to remedy that breach within [ * ] after receiving written notice requiring it to do so;

			
		 	 (c)
	  	 the other Party does not pay any amount payable under this Agreement within [ * ] of the due date; or

			
		 	 (d)
	  	 as a result of a Force Majeure Event, either Party performance of its obligations under this Agreement is not resumed within [ * ] after notice from the other
Party.

		
	 12.3
	 	 Either Party may terminate the Agreement without cause by giving the other Party [ * ] written notice.

		
	13.	 	CONSEQUENCES OF TERMINATION
		
	 13.1
	 	 Any termination or expiry of this Agreement shall not affect any accrued rights or liabilities of either Party nor shall it affect the coming into
force or continuation in force of any other Clauses and provisions of this Agreement which are expressly or by implication intended to come into force or continue in force on or after termination or expiry of this Agreement.

		
	 13.2
	 	 Upon termination of this Agreement, both Parties shall provide mutual reasonable assistance to facilitate the orderly wind down the Services without
adverse effect to any patient or donor.

		
	 13.3
	 	 Within [ * ] of the termination of the Agreement each Party shall return, destroy, or otherwise dispose of, as requested by the owner, all property
(including Proprietary Information)(excluding patients medical records) in its possession belonging to the other Party excluding this agreement.

		
	14.	 	ASSIGNMENT
		
	 14.1
	 	 Except to any member of its Group by giving prior written notice to the other Party of [ * ], neither Party may assign, transfer or
otherwise dispose of any of its rights, transfer or otherwise dispose of any of its obligations under this Agreement without the prior written consent of the other Party, which shall not be unreasonably withheld or delayed.

		
	15.	 	NOTICES
		
	 15.1
	 	 Any notice or other communication to be given under this Agreement to a Party shall be in writing and may be delivered or sent by traceable courier,
facsimile or email to the Party to be served at its address set out below:

  
 [ * ] =
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 
  
  

 

			
	 The City Hospital – Prima Apheresis and CVacTM Agreement
	  	Page 13

			
	 (a)
	  	 to The City Hospital at:

		
		  	 PO Box 505004, Dubai UAE

		
		  	 Fax: +971 4 435 9900

		
		  	 Email: tarek.fathey@thecityhospital.com

		
		  	 Marked for the attention of: Dr. Tarek Fathey

		
	 (b)
	  	 to Prima at:

		
		  	 Dubai Healthcare City
 UAE
 Fax: 00971 4 4574099

Email: hind.alsaadi@primabiomed.com.au
 Marked for the attention of: General Manager

		
		  	 With a copy to:
 1233 High Street
 Armadale VIC 3143

Australia
 Fax
+61 3 9822 7735
 Email: martin.rogers@primabiomed.com.au
 Marked for the attention of: Chief Executive Officer

  

			
	 15.2
	  	 In proving service of a notice or document it shall be sufficient to prove that delivery was made and recorded or that the facsimile or email message was
properly addressed and despatched, as the case may be.

		
	 16.
	  	 WHOLE AGREEMENT

		
	 16.1
	  	 This Agreement contains the whole agreement between the parties relating to the transactions contemplated by this Agreement and supersedes all previous
agreements between the parties relating to these transactions.

		
	 16.2
	  	 Each Party acknowledges that, in agreeing to enter into this Agreement, it has not relied on any express or implied representation, warranty, collateral
contract or other assurance (except those set out in this Agreement and the documents referred to in it) made by or on behalf of the other Party at any time before the date of this Agreement. Each Party waives all rights and remedies which, but for
this section, might otherwise be available to it in respect of any such representation, warranty, collateral contract or other assurance.

		
	 16.3
	  	 Nothing in this section limits or excludes any liability for fraud.

  
 [ * ] =
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 
  
  

 

			
	 The City Hospital – Prima Apheresis and CVacTM Agreement
	  	Page 14

			
	 17.
	  	 DISPUTES

		
	 17.1
	  	 Any dispute arising out of or in connection with this Agreement (a “Dispute”) shall be referred by either Party first to the Chief Executive
Officers (or Managing Director or similar) of each Party.

		
	 17.2
	  	 If the Dispute is not resolved by agreement in writing between the parties within [ * ] after the date of the notice to the Chief Executive Officer,
the Dispute shall on notice in writing being given by either Party to the other (the “Arbitration Notice”) be referred to arbitration before a single arbitrator who shall be appointed by agreement in writing between the parties or,
if they are unable to agree on the identity of the arbitrator within [ * ] after Arbitration Notice is given, or if the person appointed is or becomes unable or unwell to act shall be appointed by the Dubai International Arbitration Centre
(“DIAC”). The arbitration shall be conducted in Dubai, UAE in the English language in accordance with the arbitration rules of the DIAC in force at the date of the Arbitration Notice.

		
	 17.3
	  	 The agreement to arbitration of disputes is without prejudice to either Party’s right to seek interim relief against the other Party (such as an
injunction through the Dubai Courts to protect its rights and interests and to enforce the obligations of the other Party).

		
	 18.
	  	 GENERAL

		
	 18.1
	  	 No partnership or agency

	
	 Nothing in this Agreement shall be deemed to constitute a partnership between the parties, nor constitute either Party as the agent of the other
Party for any purpose and neither Party shall have the authority or power to bind the other Party or to accept any order binding on the other Party or to contract in the name of the other Party or to create a liability against the other Party or to
pledge or purport to pledge the other Party’s credit in anyway or for any purpose.

		
	 18.2
	  	 Neither Party shall be responsible for acts of default of the other Party of the other Party’s Personnel.

		
	 18.3
	  	 Counterparts

	
	 This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same agreement, and any Party
may enter into this Agreement by executing a counterpart.

		
	 18.4
	  	 Waiver

	
	 The rights of each Party under this Agreement:

  

			
	 (a)
	  	 may be exercised as often as necessary;

		
	 (b)
	  	 are cumulative and not exclusive of rights or remedies provided by law; and

  
 [ * ] =
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 
  
  

 

			
	The City Hospital – Prima Apheresis and CVacTM Agreement	  	Page 15

					
		 	 (c)
	  	 may be waived only in writing and specifically.

	
	 Delay in the exercise or non-exercise of any right is not a waiver of that right.

		
	 18.5
	 	 Amendments

	
	 Any amendment of this Agreement shall not be binding on the parties unless set out in writing, expressed to amend this Agreement and signed by
authorised representatives of each of the parties.

		
	 18.6
	 	 Severability

	
	 If any term of this Agreement is or becomes illegal, invalid or unenforceable in any jurisdiction, that shall not affect:

			
		 	 (a)
	  	 the legality, validity or enforceability in that jurisdiction of any other term of this Agreement; or

			
		 	 (b)
	  	 the legality, validity or enforceability in other jurisdictions of that or any other provision of this Agreement.

		
	 18.7
	 	 Further assurance

	
	 Each Party undertakes, at the request and cost and expense of the other Party, to sign all documents and to do all other acts which may be necessary
to give full effect to this Agreement.

		
	 18.8
	 	 Costs

	
	 Each Party shall pay the costs and expenses incurred by it in connection with the entering into of this Agreement.

		
	 18.9
	 	 Third Party Rights

	
	 Except for an Affiliate of a Party, a person who is not a Party to this Agreement may not enforce any of its terms.

		
	 19.
	 	 GOVERNING LAW AND JURISDICTION

	
	 Except as explicitly set forth in section 7 regarding Intellectual Property Rights and Proprietary Information which shall be interpreted according
to United States patent and copyright laws, this Agreement shall be governed by and construed under the laws of the Emirate of Dubai and all applicable federal laws of the UAE, without reference to principles of conflict of laws, and shall be
subject to the exclusive jurisdiction of the civil courts of the Emirate of Dubai.

	
	 THIS AGREEMENT has been signed on behalf of the parties by their duly authorised representatives with an Effective Date which appears on page
1.

  
 [ * ] =
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 
  
  

 

			
	The City Hospital – Prima Apheresis and CVacTM Agreement	  	Page 16

 IN WITNESS WHEREOF, the undersigned have duly executed this Agreement as of the date
first set forth above. 
  

			
	 Executed for and on behalf of Prima BioMed Limited by:
	 	
		
	 /s/ Hind Al Saadi
	 	
		
	 Hind Al Saadi
	 	
	 Print Name
	 	
		
	 Executed for and on behalf of The City Hospital FZ LLC by:
	 	
		
	 /s/ Tarek Fathey
	 	
		
	 Dr. Tarek Fathey
	 	
	 Print name
	 	

  
 [ * ] =
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 
  
  

 

			
	The City Hospital – Prima Apheresis and CVacTM Agreement	  	Page 17

 SCHEDULE A 
 THERAPEUTIC APHERESIS PROGRAM 
 The City Hospital and Prima agree to provide their mutual
Services, as detailed in Schedules C and D, as well as all additional reasonable mutual support, to implement a successful Therapeutic Apheresis Program as follows. 
 [ * ] 

  
 [ * ] =
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 
  
  

 

			
	The City Hospital – Prima Apheresis and CVacTM Agreement	  	Page 18

 SCHEDULE B 
 CVAC PROGRAM 
 City Hospital and Prima agree to provide their mutual Services, as detailed
in Schedules C and D, as well as all additional reasonable mutual support, to implement a successful CVac Program as follows: 

[ * ] 

  
 [ * ] =
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 
  
  

 

			
	The City Hospital – Prima Apheresis and CVacTM Agreement	  	Page 19

 SCHEDULE C 
 CITY HOSPITAL SERVICES 
 In support of the Therapeutic Apheresis Program
and the CVac Program, City Hospital shall be responsible for providing the following Services, or for ensuring that City Hospital Personnel provide such Services. Unless otherwise specified, City Hospital is fully responsible for any and all costs
related to the provision of City Hospital Services. 
 [ * ] 

  
 [ * ] =
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 
  
  

 

			
	The City Hospital – Prima Apheresis and CVacTM Agreement	  	Page 20

 SCHEDULE D 
 PRIMA SERVICES 
 In support of the Therapeutic Apheresis Program and the
CVac Program, Prima shall be responsible for providing the following Services, or for ensuring that Prima Personnel provide such Services. Unless otherwise specified, Prima is fully responsible for any and all costs related to the provision of Prima
Services. 
 [ * ] 

  
 [ * ] =
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 
  
  

 

			
	The City Hospital – Prima Apheresis and CVacTM Agreement	  	Page 21Amended and Restated Severance Agreement between the Company and Robert C. Warre

 Exhibit 10.1 
 March 10, 2012 
 Robert C. Warren, Jr. 

President and Chief Executive Officer 
 Cascade
Corporation 
 P.O. Box 20187 

Portland, Oregon 97294-0187 
 Dear Bob:

 The Compensation Committee of the Board of Directors of Cascade Corporation (“Cascade”) has recommended, and the
Board has approved, an updating of your special severance benefit program This letter agreement (“Agreement”) describes the severance benefits, the circumstances under which they would be payable, and certain limitations on their overall
value. It includes a noncompetition agreement, which was a condition established by the Board. It replaces your current severance agreement, which will terminate upon your acceptance of the terms set forth herein. 

Your Severance Benefits will become payable, subject to the terms and conditions of this Agreement, in the event of the Involuntary
Termination of your employment within twelve months following a Change in Control of Cascade. Capitalized terms not otherwise defined in this Agreement are defined on Attachment A. 

 

	I.	SEVERANCE BENEFITS 

 Your
Severance Benefits will consist of the following: 
  

	 	A.	A lump sum cash payment equal to 2.99 times your Average Compensation will be made within 74 days of Involuntary Termination. 

 Robert C. Warren, Jr. 
 March 10, 2012 
  Page
 2
 
  
  

	 	B.	Each of your outstanding Equity Awards, if not then vested, exercisable, or otherwise free from restrictions, will accelerate automatically upon the Involuntary
Termination of your employment so that the Equity Award becomes fully vested, immediately exercisable, and free from restrictions, for the full number of Cascade shares of common stock subject to the Equity Award. Each such accelerated Equity Award,
together with all your other vested Equity Awards, will remain exercisable until the earlier of (i) the expiration of the Equity Award term or (ii) one year following the Involuntary Termination of your employment.

  

	 	C.	Cascade will at its expense provide you and your eligible dependents continued Health Coverage under Cascade’s medical/dental/vision plans or substantially similar
coverage under the purchase of an individual policy or other arrangement, without regard to any COBRA-triggering event, until the earlier of (i) 24 months after your Involuntary Termination date or (ii) the first date you are covered
under another health benefit program (except entitlement to benefits under Medicare) which provides substantially the same level of benefits without exclusion for pre-existing medical conditions. This coverage will satisfy all obligation of Cascade
to provide or make available continued Health Coverage to you and your eligible dependents under Code Section 4980B by reason of the termination of your employment. Neither you nor your eligible dependents will be entitled to any additional
period of coverage under Section 4980B as a result of the Involuntary Termination of your employment. 

  

	 	 	All benefits provided to you pursuant to this paragraph that are not exempt from taxation under Code Sections 105 or 106 must be paid (directly or on your behalf) not
later than the last day of the second calendar year following the calendar year of your Involuntary Termination The total amount of such benefits (except benefits described in Treasury Regulation Sections 1.409A-1(a)(5) or 1.409A-(b)(9)(v)) shall
not exceed two times the lesser of (i) the sum of your annualized compensation based upon your annual salary in the year preceding the year of your Involuntary Termination (adjusted for any increase during that year that was expected to
continue indefinitely if your employment had not terminated) or (ii) the applicable dollar limit under Code Section 401(a)(17) for the calendar year of your Involuntary Termination. 

 Robert C. Warren, Jr. 
 March 10, 2012 
  Page
 3
 
  
  

	II.	NONCOMPETITION AND NONSOLICITATION 

 In consideration for Cascade’s commitments in this Agreement, you agree that, for the 24-month period following the termination of your Cascade employment for any reason, you will not: 

 

	 	A.	Directly or indirectly, whether for your own account, or as an employee, director, consultant, or advisor, provide services to any business which is at the time in
competition with any Cascade then-existing or formally planned product line anywhere in the world; 

  

	 	B.	Directly or indirectly encourage or solicit any individual to leave Cascade’s employ for any reason or interfere in any other manner with the actual or prospective
employment relationships at the time existing between Cascade and its current or prospective employees; 

  

	 	C.	Induce or attempt to induce any customer, supplier, distributor, licensee, or other business affiliate of Cascade to cease doing business with Cascade or in any way
interfere with the existing business relationship between any such customer, supplier, distributor, licensee or other business affiliate and Cascade. 

 If, in any judicial proceeding, a court refuses to enforce this covenant not to compete because it covers too extensive a geographic area or is too long in its duration, it shall be reformed and enforced
to the maximum extent permitted under applicable law. 
 Cascade’s obligation to pay Severance Benefits to you under this
Agreement will terminate if you breach the noncompetition obligation set forth in this section. 
 You acknowledge that monetary
damages may not be sufficient to compensate Cascade for any economic loss which it may incur by reason of your breach of the foregoing restrictive covenants. In the event of any such breach, Cascade will, in addition to the cessation of any
remaining benefits under this Agreement and any remedies available at law, be entitled to obtain equitable relief in the form of an injunction precluding you from continuing to engage in such breach. 

 Robert C. Warren, Jr. 
 March 10, 2012 
  Page
 4
 
  
  

	III.	LIMITATION ON BENEFITS 

 The
following limitations apply to your Severance Benefits in order to assure that payments to you will not be subject to a 20% penalty tax, and will be deductible to Cascade: 

 

	 	A.	Reduction for Excess Parachute Payments. In the event that any portion of the Total Payments payable to you in connection with your Involuntary Termination after
a Change in Control would constitute an “excess parachute payment” within the meaning of Code Section 280G(b) that would be subject to the excise tax imposed on so-called excess parachute payments pursuant to Code Section 4999
(an “Excise Tax”), then the payments otherwise payable under this Agreement will be reduced to the largest amount payable to you which would result in no portion of the Total Payments being subject to the Excise Tax.

  

	 	B.	Application. For purposes of this section: 

  

	 	(i)	No portion of the Total Payments, the receipt or enjoyment of which you have effectively waived in writing prior to the date of payment, will be taken into account;

  

	 	(ii)	No portion of the Total Payments will be taken into account which, in the opinion of tax counsel selected by Cascade and reasonably acceptable to you (“Tax
Counsel”), does not constitute a “parachute payment” within the meaning of Code Section 280G; 

  

	 	(iii)	If you and Cascade disagree whether any payment will result in an Excise Tax, the matter will be conclusively resolved by an opinion of Tax Counsel;

  

	 	(iv)	You agree to provide Tax Counsel with all financial information necessary to determine the after-tax consequences of payments of Severance Benefits for purposes of
determining whether, or to what extent, Severance Benefits are to be reduced pursuant to Paragraph A above; and 

  

	 	(v)	The value of any noncash benefit or any deferred payment or benefit included in the Total Payments, and whether or not all or a portion of any payment or benefit is a
“parachute payment” for purposes of this section, will be determined by Cascade’s independent accountants in accordance with the principles of Code Section 280G(d)(3) and (4). 

 Robert C. Warren, Jr. 
 March 10, 2012 
  Page
 5
 
  
  

	 	C.	Effect on Other Agreements. In the event that any other agreement, plan, or arrangement provides for Other Payments (an “Other Agreement”), Cascade and
you agree that the Other Payment governed by such Other Agreement will be subject to the reduction in payments under Paragraph A above. To the extent possible, Cascade and you agree that reductions in benefits under any plan, program, or arrangement
of Cascade will be reduced (only to the extent described in Paragraph A above) in the following order of priority: 

  

	 	(i)	Cash payments under this Agreement; 

  

	 	(ii)	Any other payments under this Agreement; 

  

	 	(iii)	Any cash payments under any Other Agreement; and 

  

	 	(iv)	The acceleration in the exercisability or vesting of any stock option or other stock-based award granted by Corporation. 

 

	 	D.	No Payment Until Severance Benefits Value and Status Determined. No Severance Benefits will be paid to you until the value of any benefit included in the Total
Payments and whether or not all or a portion of any payment or benefit is a “parachute payment” for purposes of this section has been determined and the status of any payments in dispute has been resolved; provided, however, that in no
case will payment of any lump sum cash payment hereunder be made later than the 15th day of the third month following the later of your taxable year or Cascade’s taxable year in which your Involuntary Termination occurs, or such later period as
permitted by Code Section 409A. However, you will be permitted to exercise your Severance-Accelerated Equity Awards at any time during the one year or shorter expiration period immediately following your Involuntary Termination.

  

	 	E.	Code Sections 280G and 4999. The limitations of this section will in all events be interpreted in such manner as to avoid the imposition of excise taxes under
Code Section 4999, and the disallowance of deductions under Code Section 280G(a), with respect to any of the benefits paid pursuant to this Agreement. 

 

	 	F.	Termination For Cause, Voluntary Termination, Termination Due to Death or Disability. Should (i) your termination constitute a Termination for Cause,
(ii) you voluntarily terminate employment, or (iii) you terminate employment due to death or disability, Cascade’s obligations under this Agreement will cease and Cascade will only be required to pay you (a) any portion of your
base salary earned for services previously rendered through the date of such termination and (b) any other employment benefits to which you are entitled as of the date of termination. 

 Robert C. Warren, Jr. 
 March 10, 2012 
  Page
 6
 
  
  

	IV.	OTHER PROVISIONS 

  

	 	A.	Conditions of Severance. As a condition to receipt of any Severance Benefits described in this Agreement, you must execute and deliver to Cascade a release
agreement, in form and substance satisfactory to Cascade, releasing all claims you have or may have against Cascade and related persons or entities, within 30 days from the date of your Involuntary Termination, and any applicable revocation period
must expire without revocation of the release. If such general release of claims is not executed within the specified timeframe or is revoked within the applicable revocation period, all Severance Benefits under this Agreement will be forfeited.

  

	 	B.	Captions. All captions are solely for convenience of the parties and will not affect the meaning or interpretation of this Agreement. 

 

	 	C.	Death. If you die after your Involuntary Termination but before payment in full of the Severance Benefits to which you become entitled under this Agreement,
those payments will be made to your estate. If you die before you exercise all your outstanding Equity Awards, then your estate, or the distributees of such Equity Awards from your estate, may exercise such Equity Awards within 12 months after your
death. In no event may any such Equity Award be exercised after the specified expiration date of the award term. 

  

	 	D.	Unsecured Debt of Cascade. Cascade will pay any benefits under this Agreement, when due, from its general assets, and no trust fund, escrow arrangement or other
segregated account will be established to fund such payment. Amounts which may become owing under this Agreement will have no priority over the claims of general creditors. 

 

	 	E.	Indemnification. You will have the benefit of indemnification provisions applicable to Officers and Directors under Cascade’s bylaws (to the maximum extent
permitted by law). 

  

	 	F.	Withholding. Cascade may withhold from any amounts payable under this Agreement such Federal, state, local or foreign taxes as shall be required to be withheld
pursuant to any applicable law or regulation. 

 Robert C. Warren, Jr. 
 March 10, 2012 
  Page
 7
 
  
  

	 	G.	Notices. Notices under this Agreement must be in writing and will be deemed given when delivered in person, one business day after being sent by overnight
courier, or four business days after being mailed by certified mail. Notices to Cascade must be addressed to Cascade Corporation, Attention: Chairman of the Board, at Cascade’s headquarters address. Notices to you are to be sent to the last
address you have provided from time to time to Cascade’s human resources department. Either party may change its address for notices by giving notice of the change to the other party. 

 

	 	H.	Miscellaneous. This Agreement will be binding upon Cascade, its successors and assigns (including, without limitation, the surviving entity in any Change in
Control) and is to be construed, enforced, and interpreted under applicable federal law and the laws of the State of Oregon (without regard to conflict of law provisions). You will not be entitled to any other Severance Benefits upon your
termination of employment. This letter may only be modified by a writing signed by you and a Cascade officer acting with the approval of the Compensation Committee. Should any provision of this Agreement be adjudged by a court of competent
jurisdiction to be unenforceable, the invalidity of that provision will in no way affect (to the maximum extent permitted by law) the application of such provision under circumstances different from those adjudicated by the court, the application of
any other provision of this Agreement, or the enforceability or validity of this Agreement as a whole. 

  

	 	I.	At-Will Employment. Nothing in this Agreement is intended to provide you with any right to continue in the employ of Cascade (or any subsidiary) for any period
or to restrict your rights or the rights of Cascade (or any subsidiary) to terminate the employment relationship at any time for any reason whatsoever or for no reason, with or without cause. 

 

	 	J.	Exemption from Code Section 409A. The benefits under this Agreement are intended to be exempt from the requirements of Code Section 409A by reason of
all payments under this Agreement being either “short-term deferrals” within the meaning of Treasury Regulation Section 1.409A-1(b)(4) or separation pay due to involuntary separation from service under Treasury Regulation
Section 1.409A-1(b)(9)(iii). All provisions of this Agreement shall be interpreted in a manner consistent with preserving these exemptions. 

 Robert C. Warren, Jr. 
 March 10, 2012 
  Page
 8
 
  
  

	 	K.	Attorney Fees. In the event you or Cascade should bring suit or action relating to the interpretation or application of any provision of this Agreement or any
benefits payable hereunder, the prevailing party will be entitled to recover reasonable attorney fees and costs incurred in connection with such proceedings. For purposes of this provision the prevailing party means the party determined by the court
to have most nearly prevailed in the proceedings, even if that party does not prevail in all matters, and does not necessarily mean the party in whose favor the judgment is actually rendered. 

Please indicate your acceptance of the foregoing provisions of this agreement by signing the enclosed copy and returning it to me.

  

			
	Cordially,
	
	CASCADE CORPORATION
		
	By	 	 /s/ James S. Osterman

		
		 	Chairman

 ACCEPTANCE 
 I hereby agree to all the terms and provisions of the foregoing letter agreement governing the Severance Benefits to which I may become entitled in connection with certain changes in control or ownership
of Cascade Corporation. 
  

			
	 /s/ Robert C. Warren, Jr.

		
	Date	 	    March 27, 2012

 Robert C. Warren, Jr. 
 March 10, 2012 
  Page
 9
 
  

ATTACHMENT A 

DEFINITIONS 
 The following
definitions apply to terms used in the above Agreement: 
 AVERAGE COMPENSATION means the average of your total annual base salary and annual
cash bonus or incentive compensation from Cascade as reported on Form W-2 for the three calendar years (five calendar years for purposes of application of the Limitations on Benefits section) or such fewer number of calendar years of employment with
Cascade completed immediately prior to the calendar year in which the Change of Control is affected. 
 BOARD means Cascade’s Board of
Directors. 
 CHANGE IN CONTROL means: 
  

	1.	Any change in the composition of Cascade’s Board over a period of 24 consecutive months or less such that a majority of the Board ceases, by reason of one or
more contested elections for Board membership, to be comprised of individuals who either (A) have been members of the Board continuously since the beginning of such period or (B) have been elected or nominated for election as Board members
described in (A) who were still in office at the time such election or nomination was approved by the Board; or 

  

	2.	The approval by the stockholders of Cascade of any plan or proposal for the liquidation or dissolution of Cascade; or 

 

	3.	Any merger or consolidation in which securities possessing more than 50% of the total combined voting power of Cascade’s outstanding securities are transferred to
persons different from the persons holding those securities immediately prior to such transaction; or 

  

	4.	The acquisition by a person or a group of related persons, other than Cascade or a person controlling, controlled or under common control with Cascade, of beneficial
ownership (as determined pursuant to Rule 13d-3 of the Securities Exchange Act of 1934) of securities possessing more than 35% of the total combined voting power of Cascade’s outstanding securities pursuant to a transaction or series of related
transactions which the Board does not at any time recommend Cascade’s shareholders accept or approve. 

 CODE means the
Internal Revenue Code of 1986, as amended. 

 Robert C. Warren, Jr. 
 March 10, 2012 
  Page
 10
 
  
 HEALTH COVERAGE
means the continued health care coverage to which you and your eligible dependents may become entitled under this Agreement upon the Involuntary Termination of your employment. 
 INVOLUNTARY TERMINATION means the termination of your Cascade employment: 
  

	5.	involuntarily upon your discharge or dismissal by Cascade (other than a Termination for Cause), or 

 

	6.	voluntarily upon your resignation following (a) a change in your position with Cascade which materially reduces your duties or level of responsibility or which
otherwise changes the level of management to which you report, (b) a 20% or more reduction in your level of base compensation or (c) a change in your place of employment which is more than 50 miles from your place of employment prior to
the Change in Control, provided and only if such change or reduction does not have your written concurrence, and that (i) within 90 days after the initial existence of such change or reduction you provide Cascade with a written notice
describing such change or reduction, (ii) Cascade fails to cure the circumstances within 30 days after Cascade receives your notice, and (iii) you terminate your employment with Cascade and all the members of Cascade’s controlled
group within 90 days of the date of your notice. 

 In no event shall an Involuntary Termination be deemed to occur if your
employment terminates by reason of your death or disability. 
 As used in this Agreement, termination of employment and similar terms mean
“separation from service” as such term is defined in Treasury Regulation Section 1.409A-1(h). 
 EQUITY AWARD means any stock
option or other stock-based award granted by Corporation under a Plan which is outstanding at the time of the Change in Control or upon your subsequent Involuntary Termination. 
 OTHER PAYMENT means any payment or benefit payable to you in connection with a Change in Control pursuant to any plan, arrangement, or agreement (other than this Agreement) with Cascade, a person whose
actions result in such Change in Control, or any person affiliated with Cascade or such person. 
 PLAN means (a) Cascade’s 1995
Incentive Stock Option Plan, as amended or restated from time to time, (b) Cascade’s Stock Appreciation Rights and Restricted Stock Plan, including the restatement of the plan approved by the shareholders in 2011,, and (b) any
successor or additional stock incentive plan subsequently implemented by Cascade. 

 Robert C. Warren, Jr. 
 March 10, 2012 
  Page
 11
 
  

SEVERANCE-ACCELERATED EQUITY AWARD means any outstanding Equity Award (or installment thereof) which accelerates upon your Involuntary Termination
pursuant to this Agreement. 
 SEVERANCE BENEFITS means the severance benefits to which you may become entitled under this Agreement in the
event of your Involuntary Termination following a Change in Control, subject, however, to the Limitation on Benefits section. 
 TERMINATION FOR
CAUSE means an Involuntary Termination of your employment by reason of your having engaged in fraud or in any other intentional misconduct adversely affecting Cascade’s business or reputation in a material manner. 

TOTAL PAYMENTS means all payments or benefits payable to you in connection with a Change in Control, including payments pursuant to this Agreement and
any Other Payments pursuant to any other plan, agreement, or arrangement with Cascade, a person whose actions result in the Change in Control, or any person affiliated with Cascade or such person.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00202-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00202-of-00352.parquet"}]]